SBC Medical Group Holdings Inc

Análisis de la acción SBC Medical Group Holdings Inc (SBC)

$5.160

-0.136 (-2.64%)Al cierre

Loading chart…
Máximo
5.350
Apertura
5.300
Precio medio ponderado por volumen
5.21
Volumen
119.49K
Capitalización
—
Mínimo
5.130
Importe
622.93K
EV/EBITDA, TTM
4.85

SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.

Análisis de IA of SBC Medical Group Holdings Inc (SBC)

Mantener

SBC Medical Group Holdings Inc is currently trading at $5.16, with a forward P/E of 9.33, indicating it may be undervalued compared to its earnings potential. However, the RSI is at 42.19, suggesting it is nearing oversold territory but not yet a strong buy signal. The company reported a gross margin of 73.14% in Q2 2026, which is solid, but the recent 4.80% decline over the last five days raises concerns about short-term volatility. Therefore, while there are positive growth indicators, the recent price drop and lack of strong momentum suggest holding off on buying for now.

Métricas de valoración

El PER previsto actual de SBC Medical Group Holdings Inc (SBC) es 9.33, frente a su media de 5 años de 4.71.

PER previsto

Sobrevalorado
Media 5A P/E
4.71
P/E actual
9.33
Sobrevalorada
8.69
Infravalorada
0.73

EV/EBITDA previsto

Muy sobrevalorado
Media 5A EV/EBITDA
1.02
EV/EBITDA actual
4.85
Sobrevalorada
2.63
Infravalorada
-0.59

Precio/ventas previsto

Sobrevalorado
Media 5A P/S
1.35
P/S actual
2.59
Sobrevalorada
2.46
Infravalorada
0.24

Cronología de eventos

2026-08-13 (ET)

07:00:00

SBC Medical Reports Q2 Revenue of $49M

2026-05-14 (ET)

06:40:00

SBC Medical Reports Q1 Revenue of $43M, Below Expectations

2026-03-27 (ET)

16:30:00

Major Averages Drop Due to Strait of Hormuz Incidents

12:00:00

Major Averages Decline Amid Middle East Tensions

06:50:00

SBC Medical Q4 Revenue at $40M, Below Consensus

Noticias

Preguntas frecuentes sobre SBC, respondidas por Alphio AI

SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics. It operates in the Industrials sector.

SBC Medical Group Holdings Inc is currently trading at $5.16, with a forward P/E of 9.33, indicating it may be undervalued compared to its earnings potential. However, the RSI is at 42.19, suggesting it is nearing oversold territory but not yet a strong buy signal. The company reported a gross margin of 73.14% in Q2 2026, which is solid, but the recent 4.80% decline over the last five days raises concerns about short-term volatility. Therefore, while there are positive growth indicators, the recent price drop and lack of strong momentum suggest holding off on buying for now.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar